The Genomics Facility combines the expertise and instrumentation of two previous shared resource laboratories, the Microarray Facility and the Molecular Diagnosis and Genotyping Facility, to provide an integrated set of services for DNA and RNA profiling. These services are delivered by experienced genomics professionals, including a newly strengthened and focused bioinformatics support staff. Abramson Cancer Center (ACC) members benefit from consultations and training available throughout their projects, including during experimental design and budget development, sample accrual. Facility quality control assays and lab work, data management and analyses, and manuscript preparation. The Facility supports quantitative RNA profiling by Affymetrix GeneChips, lllumina BeadChips, real-time PCR, Sequenom custom multiplex assays, and High-Throughput Genomics custom profiling. DNA profiling of custom panels of sequence polymorphisms are conducted by quantitative PCR, Sequenom assays, and lllumina GoldenGate genotyping, while whole-genome assays are available on Affymetrix SNP GeneChip and lllumina Infinium platforms. Several other services including microRNA profiling, epigenetic DNA assays, and translational molecular diagnostics for clinical research are offered using these platforms. Massively parallel sequencing on an lllumina Solexa Genome Analyzer expands existing assays with genomic coverage and resolution not previously possible, and creates opportunities for new genomics applications in cancer biology. The integration of all these services facilitates gene discovery, functional characterization, and other basic research efforts to elucidate the molecular pathogenesis of human cancers. In addition, molecular profiling at the DNA and RNA levels can be used to assist Abramson Cancer Center investigators in cancer diagnosis, subclassification, risk prediction and selection of appropriate therapy. Over 70 ACC members used the facility in the last year. ACC member usage was 34% of the total core usage. CCSG support represents 8% of the proposed core budget with the remaining funding from charge backs, grants/contracts, and institutional support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-38
Application #
8593268
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$291,149
Indirect Cost
$86,401
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32
Huang, Mo; Wang, Jingshu; Torre, Eduardo et al. (2018) SAVER: gene expression recovery for single-cell RNA sequencing. Nat Methods 15:539-542
Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov :
Onorati, Angelique V; Dyczynski, Matheus; Ojha, Rani et al. (2018) Targeting autophagy in cancer. Cancer 124:3307-3318
Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Romero, Sally A D; Brown, Justin C; Bauml, Joshua M et al. (2018) Barriers to physical activity: a study of academic and community cancer survivors with pain. J Cancer Surviv 12:744-752
Scheel, John R; Kim, Eunhee; Partridge, Savannah C et al. (2018) MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol 210:1376-1385
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298

Showing the most recent 10 out of 1047 publications